Literature DB >> 35377935

Reversal Agents in Sedation and Anesthesia Practice for Dentistry.

Michelle Wong1.   

Abstract

Reversal agents are defined as any drug used to counteract the pharmacologic effects of another drug. Several pharmacologic antagonists serve as essential drugs in the contemporary practices of sedation providers and anesthesiologists. Reversal or "antidote" drugs, such as flumazenil and naloxone, are often used in unintentional overdose situations involving significant benzodiazepine- and/or opioid-induced respiratory depression. Within the context of skeletal muscle relaxation, neostigmine and sugammadex are routinely used to reverse the effects of nondepolarizing neuromuscular blocking agents. In addition, the alpha-adrenergic antagonist phentolamine is used in dentistry as a local anesthetic reversal agent, decreasing its duration of action by inducing vasodilation. This review article discusses the pharmacology, uses, practical implications, adverse effects, and precautions needed for flumazenil, naloxone, neostigmine, sugammadex, and phentolamine within the context of sedation and anesthesia practice for dentistry.

Entities:  

Keywords:  Anesthesia; Antidote; Flumazenil; Naloxone; Neostigmine; Opioid; Overdose; Phentolamine; Reversal agent; Sugammadex

Mesh:

Substances:

Year:  2022        PMID: 35377935      PMCID: PMC8985463          DOI: 10.2344/anpr-69-01-09

Source DB:  PubMed          Journal:  Anesth Prog        ISSN: 0003-3006


  24 in total

1.  Tricyclic antidepressant overdose.

Authors:  R Lynch
Journal:  Emerg Med J       Date:  2002-11       Impact factor: 2.740

2.  The fallacy of a lifesaving sublingual injection of flumazenil.

Authors:  Joel M Weaver
Journal:  Anesth Prog       Date:  2011

3.  Guidelines on muscle relaxants and reversal in anaesthesia.

Authors:  Benoît Plaud; Christophe Baillard; Jean-Louis Bourgain; Gaëlle Bouroche; Laetitia Desplanque; Jean-Michel Devys; Dominique Fletcher; Thomas Fuchs-Buder; Gilles Lebuffe; Claude Meistelman; Cyrus Motamed; Julien Raft; Frédérique Servin; Didier Sirieix; Karem Slim; Lionel Velly; Franck Verdonk; Bertrand Debaene
Journal:  Anaesth Crit Care Pain Med       Date:  2020-01-08       Impact factor: 4.132

4.  Consensus guidelines for the management of postoperative nausea and vomiting.

Authors:  Tong J Gan; Pierre Diemunsch; Ashraf S Habib; Anthony Kovac; Peter Kranke; Tricia A Meyer; Mehernoor Watcha; Frances Chung; Shane Angus; Christian C Apfel; Sergio D Bergese; Keith A Candiotti; Matthew Tv Chan; Peter J Davis; Vallire D Hooper; Sandhya Lagoo-Deenadayalan; Paul Myles; Greg Nezat; Beverly K Philip; Martin R Tramèr
Journal:  Anesth Analg       Date:  2014-01       Impact factor: 5.108

Review 5.  Take-home naloxone.

Authors:  Thara Kumar; Hans Rosenberg
Journal:  CMAJ       Date:  2017-09-18       Impact factor: 8.262

6.  Incidence of Anaphylaxis Associated With Sugammadex.

Authors:  Yusuke Miyazaki; Hiroshi Sunaga; Kotaro Kida; Shotaro Hobo; Nobuyoshi Inoue; Masayuki Muto; Shoichi Uezono
Journal:  Anesth Analg       Date:  2018-05       Impact factor: 5.108

7.  Comparison of routes of flumazenil administration to reverse midazolam-induced respiratory depression in a canine model.

Authors:  M S Heniff; G P Moore; A Trout; W H Cordell; D R Nelson
Journal:  Acad Emerg Med       Date:  1997-12       Impact factor: 3.451

8.  Practice Guidelines for Moderate Procedural Sedation and Analgesia 2018: A Report by the American Society of Anesthesiologists Task Force on Moderate Procedural Sedation and Analgesia, the American Association of Oral and Maxillofacial Surgeons, American College of Radiology, American Dental Association, American Society of Dentist Anesthesiologists, and Society of Interventional Radiology.

Authors: 
Journal:  Anesthesiology       Date:  2018-03       Impact factor: 7.892

9.  Flumazenil reversal of sublingual triazolam: a randomized controlled clinical trial.

Authors:  Kazuo Hosaka; Douglass Jackson; Jacqueline E Pickrell; Masahiro Heima; Peter Milgrom
Journal:  J Am Dent Assoc       Date:  2009-05       Impact factor: 3.634

10.  Answering a Call to Action on American Workplace and Community Opioid Concerns.

Authors:  Peter Harnett; John Hindman; Melissa Duenas; Michael Coogan; Heather Misicko
Journal:  New Solut       Date:  2021-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.